

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

**per Navneet Rai Kabra**

Partner

Membership No.: 102328

UDIN: 24102328 BKEXOC 2532

Place: Hyderabad

Date: August 07, 2024



Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2024

(Rupees in millions)


	Quarter Ended			Year ended
	30-Jun-24 (Unaudited)	31-Mar-24 (Audited) Refer Note 2	30-Jun-23 (Unaudited)	31-Mar-24 (Audited)
1 Income				
(a) Revenue from operations	3,274	3,048	2,989	12,221
(b) Other income	53	39	38	155
Total Income	3,327	3,087	3,027	12,376
2 Expenses				
(a) Purchase of medical consumables, drugs and surgical instruments	645	594	657	2,536
(b) (Increase)/decrease in inventories of medical consumables, drugs and surgical instruments	(10)	13	(43)	(29)
(c) Employee benefits expense	615	561	534	2,196
(d) Other expenses	1,086	1,017	918	3,874
(e) Finance cost	38	23	1	36
(f) Depreciation and amortisation expense	137	204	121	581
Total Expenses	2,511	2,412	2,188	9,194
3 Profit before tax (1-2)	816	675	839	3,182
4 Tax expense				
(a) Current tax	218	180	211	817
(b) Deferred tax (credit)/charge	(9)	(5)	2	(6)
(c) Adjustment of tax relating to earlier periods/years	-	18	-	18
Total tax expenses	209	193	213	829
5 Profit for the period/year (3-4)	607	482	626	2,353
6 Other comprehensive income/(loss)				
Items that will not be reclassified subsequently to statement of profit and loss				
- Re-measurement gain/(loss) on defined benefit plans	1	(4)	3	3
- Income tax effect	-	1	(1)	(1)
Other comprehensive income/(loss), net of tax	1	(3)	2	2
7 Total comprehensive income (5+6)	608	479	628	2,355
8 Paid up equity share capital (face value of Rs.10 each)				800
9 Other Equity				17,864
10 Earnings per share (of Rs.10 each) : (not annualised for the quarter ended)				
(a) Basic (Rs.)	7.58	6.02	7.83	29.41
(b) Diluted (Rs.)	7.58	6.02	7.83	29.41



Notes:

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2024 ("Unaudited Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 07 August 2024 and have been subject to limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The standalone figures for the quarter ended 31 March 2024 are the balancing figure between the audited standalone figures in respect of the full financial year 2023-24 and the published unaudited year to date standalone figures up to the third quarter of the previous financial year 2023-24.
- 3 The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 4 The Board of Directors, at their meeting held on June 28, 2024, recommended for the sub-division of equity shares of the Company from existing face value of Rs. 10/- each to face value of Rs. 2/- each (i.e. split of 1 equity share of Rs.10/- each into 5 equity shares of Rs.2/- each), subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company and other regulatory approvals.
- 5 Subsequent to the current quarter, the Company has entered into a Share Purchase agreement for acquisition of 100% of the equity shares of Chalasani Hospitals Private Limited (Queen's NRI Hospital) for a total cash consideration of Rs.750 Mn.
- 6 The Company operates in one single reportable business segment- "Medical and Healthcare services".
- 7 The above Unaudited Standalone Financial Results of the Company are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf of the Board
Krishna Institute of Medical Sciences Limited



Dr. B Bhaskara Rao
Managing Director
DIN: 00008985

Hyderabad
07 August 2024



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and an associate for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S.No.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Hospital Bengaluru Private Limited	Subsidiary
10	Sarvejana Healthcare Private Limited	Subsidiary
11	Rajyalakshmi Healthcare Private Limited	Subsidiary



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

S.No.	Entity	Relationship
12	Spanv Medisearch Lifesciences Private Limited	Subsidiary
13	KIMS Manavata Hospitals Private Limited	Subsidiary
14	Meda Institute of Podiatry Private Limited *	Subsidiary
15	Kondapur Healthcare Limited (Formerly known as RVM Healthcare Limited)	Associate

* Became a subsidiary during the current quarter.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
- Three subsidiaries, whose unaudited interim financial results include total revenue of Rs. Nil, total net loss after tax of Rs. 0.84 million, total comprehensive loss of Rs. 0.84 million, for the quarter ended June 30, 2024, as considered in the Statement which have been reviewed by their respective independent auditors.
 - An associate, whose unaudited interim financial results include Group's share of net loss of Rs. Nil and Group's share of total comprehensive loss of Rs. Nil for the quarter ended June 30, 2024, as considered in the Statement whose interim financial results and other financial information has been reviewed by their respective independent auditor.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004



per Navneet Rai Kabra
Partner

Membership No.: 102328

UDIN: 24102328BKERDD5404

Place: Hyderabad

Date: August 07, 2024



Statement of Unaudited Consolidated Financial Results for the Quarter ended 30 June 2024

(Rupees in millions)

		Quarter ended			
		30-Jun-24	31-Mar-24	30-Jun-23	Year ended
		(Unaudited)	(Audited) Refer Note 2	(Unaudited)	31-Mar-24 (Audited)
1	Income				
	(a) Revenue from operations	6,884	6,338	6,060	24,981
	(b) Other income	46	38	31	131
	Total Income	6,930	6,376	6,091	25,112
2	Expenses				
	(a) Purchase of medical consumables, drugs and surgical instruments	1,448	1,352	1,347	5,369
	(b) Increase in inventories of medical consumables, drugs and surgical instruments	(22)	(9)	(47)	(66)
	(c) Employee benefits expense	1,186	1,085	1,039	4,224
	(d) Other expenses	2,478	2,320	2,150	9,051
	(e) Finance costs	179	164	93	470
	(f) Depreciation and amortisation expenses	390	463	323	1,465
	Total Expenses	5,659	5,375	4,905	20,513
3	Profit before share of loss from associate (1-2)	1,271	1,001	1,186	4,599
4	Share of loss from associate, net of tax	-	(1)	-	(3)
5	Profit before tax (3+4)	1,271	1,000	1,186	4,596
6	Tax expense				
	(a) Current tax	338	262	319	1,162
	(b) Deferred tax (credit)/charge	(19)	(2)	-	40
	(c) Adjustment of tax relating to earlier periods/years	-	25	-	34
	Total tax expenses (6)	319	285	319	1,236
7	Profit for the period/year (5-6)	952	715	867	3,360
	Attributable to:				
	Owners of the company	866	655	808	3,101
	Non controlling interests	86	60	59	259
8	Other comprehensive (loss)/ income for the period/year				
	Items that will not be reclassified subsequently to statement of profit and loss				
	- Re-measurement (loss)/gain on defined benefit plans	1	(4)	3	4
	- Income tax effect	-	1	(1)	(1)
	Other comprehensive (loss)/ income, net of tax	1	(3)	2	3
	Attributable to:				
	Owners of the company	1	(3)	2	3
	Non controlling interests	-	-	-	-
9	Total comprehensive income (7+8)	953	712	869	3,363
	Owners of the company	867	652	810	3,104
	Non controlling interests	86	60	59	259
	Total comprehensive income	953	712	869	3,363
10	Paid up equity share capital (face value of Rs.10 each)				800
11	Other Equity				17,483
12	Earnings per share (of Rs.10 each): (not annualised for the quarter ended)				
	(a) Basic (Rs.)	10.82	8.18	10.10	38.75
	(b) Diluted (Rs.)	10.82	8.18	10.10	38.75



Notes:

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2024 ("Unaudited Consolidated Financial Results") of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company"), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the "Group") and its associate has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 7 August 2024 and have been subject to limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Consolidated figures for the quarter ended 31 March 2024 are the balancing figure between the audited consolidated figures in respect of the full financial year 2023-24 and the published unaudited year to date consolidated figures up to the third quarter of the previous financial year 2023-24.
- 3 The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 4 The Board of Directors, at their meeting held on June 28, 2024, recommended for the sub-division of equity shares of the Company from existing face value of Rs. 10/- each to face value of Rs. 2/- each (i.e. split of 1 equity share of Rs.10/- each into 5 equity shares of Rs.2/- each), subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company and other regulatory approvals.
- 5 Subsequent to the current quarter, the Company has entered into a Share Purchase agreement for acquisition of 100% of the equity shares of Chalasani Hospitals Private Limited (Queen's NRI Hospital) for a total cash consideration of Rs.750 Mn.
- 6 The Group operates in one single reportable business segment- "Medical and Healthcare services".
- 7 The above Unaudited Consolidated Financial Results of the Group are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf of the Board
Krishna Institute of Medical Sciences Limited


Dr. B Bhaskara Rao
Managing Director
DIN: 00008985



Hyderabad
07 August 2024

